| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Tandem Diabetes Care, Inc.'s insiders have reduced their positions by a net 1,700 shares worth roughly $33K. In the past 30 days, 0 insiders bought and 1 sold.
The insider who sold still holds shares after the sale.
Counted by filing, the last 12 months brought no open-market purchases and 3 sales by 2 insiders worth about $37K. The 12 months before that brought 4 open-market purchases by 4 insiders worth about $455K and 1 sale by 1 insider worth about $1.2M.
2 of the 3 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
The largest open-market purchase in the last two years was 10,538 shares by Jean-Claude Kyrillos (EVP & Chief Operating Officer) at an average $18.12 on March 7, 2025, about $191K. Twelve months later TNDM was up 18%.
The most recent purchase was by John F Sheridan (President & CEO) on August 11, 2025.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 160.3K | $2.83M | - | |
| VP | 52.8K | $931.7K | - | |
| CFO | 52.0K | $918.5K | - | |
| VP | 40.3K | $711.6K | - | |
| VP | 32.1K | $567.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | Christopher J Twomey59 | Director | Sale+OE10b5-1 | 1,700 | $19.15 | $32,555.00 | -6.5% | - | - | |
| Mar 17, 2026 | Mark David Novara | EVP & Chief Commercial Officer | Sale+OE | 187 | $23.05 | $4,310.35 | -0.5% | -29.9% | - | |
| Mar 5, 2026 | Mark David Novara | EVP & Chief Commercial Officer | Sell10b5-1 | 2 | $22.81 | $45.62 | - | -20.3% | - | |
| Aug 11, 2025 | John F Sheridan55 | President & CEO | Buy | 10,000 | $10.23 | $102,318.00 | +10.4% | +61.8% | +131.7% | |
| Aug 8, 2025 | Leigh Vosseller76 | EVP & Chief Financial Officer | Buy | 13,720 | $10.89 | $149,403.94 | +115.7% | +18.7% | +99.3% | |
| Mar 7, 2025 | Jean-Claude Kyrillos | EVP & Chief Operating Officer | Buy | 10,538 | $18.12 | $190,966.47 | New | +15.0% | +17.7% | |
| Nov 21, 2024 | Kim D Blickenstaff61 | Director | Sell | 40,000 | $31.04 | $1,241,400.00 | -19.5% | +3.2% | -30.8% | |
| Nov 15, 2024 | Mark David Novara | EVP & Chief Commercial Officer | Buy | 532 | $23.24 | $12,363.68 | New | +19.3% | -31.9% | |
| May 30, 2024 | Dick Allen69 | Director | Sell | 5,000 | $51.68 | $258,400.00 | -100% | -16.9% | -62.9% | |
| Nov 27, 2023 | Dick Allen69 | Director | Buy | 5,000 | $18.96 | $94,777.50 | +33.4% | +48.2% | +54.3% |